Last reviewed · How we verify
NCT06961760
Expanded Access Program for CT1812 (Zervimesine)
trial testing zervimesine in Dementia With Lewy Bodies. No longer available.
Quick facts
| Lead sponsor | Cognition Therapeutics |
|---|---|
| Status | NO LONGER AVAILABLE |
| Study type | EXPANDED_ACCESS |
| Sites | 8 locations across United States |
Drugs / interventions tested
- zervimesine — full drug profile →
Conditions studied
- Dementia With Lewy Bodies — all drugs for Dementia With Lewy Bodies →
Sponsor
Cognition Therapeutics — full company profile →
Who can join
Adults 50 to 86, any sex, with Dementia With Lewy Bodies. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multi-center, open label, expanded access program (EAP) that will provide 100 mg CT1812 for up to one year to participants with mild-to-moderate DLB.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06961760
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dementia With Lewy Bodies
Currently open trials in the same condition.
- NCT06357195 — DIAMOND-Lewy Guidelines for Antipsychotic Use in Older Patients · active not recruiting
- NCT06389032 — PERSEVERE: Peer Mentor Support and Caregiver Education in Lewy Body Dementia · NA · active not recruiting
- NCT06467461 — Identification of Prodromal Neurodegeneration in Serotonergic-Induced REM Sleep Behavior Disorder · NA · recruiting
- NCT06005935 — Environmental and Reproductive Health Risk for Lewy Body Dementia · active not recruiting
- NCT05460143 — Optical Neuroimaging and Cognition · recruiting
Other Cognition Therapeutics trials
Trials by the same sponsor.
- NCT05893537 — Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry A · Phase 2 · terminated
- NCT05225415 — Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy B · Phase 2 · completed
- NCT05248672 — Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers · Phase 1 · completed
- NCT05225389 — Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects · Phase 1 · completed
- NCT04735536 — Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06961760 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cognition Therapeutics
- Last refreshed: 21 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06961760.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing